US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,428.60

-5.1395-0.36%

Number of Gainers:12

Number of Losers:8

Number of Flat:- -

PE:- -

High:1,435.08

Open:1,435.08

Low:1,419.99

Close:1,433.74

Loading ...

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

AHCO vs. ABT: Which Stock Is the Better Value Option?

Pfizer could use existing US manufacturing to counter potential tariff hit

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

MT Newswires Live

Gilead Sciences sets aside $200 million to resolve HIV drug probe

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Pfizer could move outside manufacturing to the US, says CEO

Pfizer comments on Q1, Q2 numbers amid higher rebate expense

Pfizer Exec Says IF There Are Significant Tariffs, Co Will TRY to Move Outside Manufacturing to the U.S.- TD Cowen Conference

THOMSON REUTERS

Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

MT Newswires Live

BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025

Genevant: Seeking Monetary Relief, Injunctions Against Spikevax &, Where Applicable, Additional Products That Moderna Represented Use Same Lnp Tech

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4568/news?page=17"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1428.6036,"timestamp":1741982399999,"preClose":1433.7432,"halted":0,"volume":80699704,"delay":0,"changeRate":-0.003585,"change":-5.139526,"pbRate":3.944289,"amount":4817314729.209033,"amplitude":0.010528,"prevYearClose":1274.8187,"fiveDayClose":1480.0557,"twentyDayClose":1396.8896,"turnoverRate":0.005218,"marketCap":1177434707433,"floatMarketCap":1157164303072,"peRate":31.483445},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1435.0837,"amplitude":0.010528,"preClose":1433.7432,"low":1419.9891,"pbRate":"3.944289","latestPrice":1428.6036,"volume":80699704,"delay":0,"open":1435.0837,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1480.0557,"twentyDayClose":1396.8896,"sixtyDayClose":1278.7518,"secType":"PLATE","market":"US","turnoverRate":0.005218,"peRate":31.483445,"marketCap":1177434707433,"floatMarketCap":1157164303072,"timestamp":1741982399999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":12,"down":8,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:17,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516958616","title":"Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2516958616","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516958616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:50","pubTimestamp":1741042206,"startTime":"0","endTime":"0","summary":"In the latest market close, Gilead Sciences  reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow experienced a drop of 1.48%, and the technology-dominated Nasdaq saw a decrease of 2.64%.The HIV and hepatitis C drugmaker's shares have seen an increase of 17.6% over the last month, surpassing the Medical sector's gain of 1.11% and the S&P 500's loss of 1.26%.The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share  are projected to be $1.73, reflecting a 231.06% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $6.78 billion, indicating a 1.36% growth compared to the corresponding quarter of the prior year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research show","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-rises-market-225006380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","BK4585","IE0002270589.USD","BK4139","BK4532","IE00B19Z3B42.SGD","LU1585245621.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","BK4578","LU0058720904.USD","LU1066053197.SGD","LU1839511570.USD","LU0289739699.SGD","BK4568","GILD","LU1430594728.SGD","LU1066051498.USD","BK4566","IE00BKVL7J92.USD","BK4588","IE00B7SZLL34.SGD","LU0109394709.USD","BK4583","IE00BSNM7G36.USD","LU2087621335.USD","LU0320765992.SGD","LU2468319806.SGD","IE00B3T34201.USD","LU0889565916.HKD","LU0234570918.USD","IE00B19Z3581.USD","BK4550"],"gpt_icon":0},{"id":"2516696813","title":"Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2516696813","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516696813?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:45","pubTimestamp":1741041911,"startTime":"0","endTime":"0","summary":"In the latest trading session, Johnson & Johnson  closed at $167.28, marking a +1.37% move from the previous day. This move outpaced the S&P 500's daily loss of 1.76%. At the same time, the Dow lost 1.48%, and the tech-heavy Nasdaq lost 2.64%.Shares of the world's biggest maker of health care products witnessed a gain of 8.46% over the previous month, beating the performance of the Medical sector with its gain of 1.11% and the S&P 500's loss of 1.26%.Investors will be eagerly watching for the performance of Johnson & Johnson in its upcoming earnings disclosure. The company is predicted to post an EPS of $2.59, indicating a 4.43% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $21.66 billion, indicating a 1.29% upward movement from the same quarter last year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-market-dipped-johnson-johnson-224511883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","LU0345769631.USD","LU2468319806.SGD","LU1162221912.USD","LU1244550221.USD","BK4534","LU0795875086.SGD","IE0002141913.USD","JNJ","LU0234572021.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4585","LU1674673428.USD","LU2430703251.USD","LU0058720904.USD","LU0320765646.SGD","LU0882574055.USD","IE00B19Z3581.USD","LU1674673691.USD","IE00B4R5TH58.HKD","BK4568","LU0912757837.SGD","LU1506573853.SGD","LU2133065610.SGD","IE00BVYPNV92.GBP","LU1221951129.SGD","LU2347655156.SGD","LU2129689605.HKD","LU1244550577.SGD","LU1057294990.SGD","LU2592432038.USD","IE00B2B36J28.USD","LU1267930813.SGD","IE00BGHQF631.EUR","IE00B42XCP33.USD","LU1196500208.SGD","LU1061106388.HKD","LU2430703178.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU0122379950.USD","LU2505996681.GBP","SG9999001440.SGD","LU1732799900.SGD","IE0002270589.USD","IE00BSNM7G36.USD","LU0234570918.USD","IE0034235303.USD","BK4559"],"gpt_icon":0},{"id":"2516944666","title":"Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516944666","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516944666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 04:00","pubTimestamp":1741032000,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s  Committee for Medicinal Products for Human Use .The CHMP recommended conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma . The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.A final decision is expected in the coming months.Regeneron’s shares have lost 30.5% in the past year compared with the medical-biomedical genetics industry’s decline of 6.7%.Regeneron Pharmaceuticals Stock Price, Consensus and EPS Surprise. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote. REGN’s oncology franchise got a boost with the European Commission","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-gets-positive-chmp-opinion-200000419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","LU0289739699.SGD","RHHBY","IE00BZ1G4Q59.USD","BK4139","LU0234570918.USD","LU0053666078.USD","LU0114720955.EUR","LU1066053197.SGD","BK4007","LU1430594728.SGD","IE00B3T34201.USD","03165","CHMP","LU0320765992.SGD","LU1917777945.USD","LU2468319806.SGD","BMRN","LU2237438978.USD","LU2023250504.SGD","GILD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4583","FL","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0882574055.USD","BK4550","LU2087621335.USD","BK4585","LU0889565916.HKD","BK4568","LU2362540622.SGD","IE00B19Z3581.USD","BK4087","LU0823416689.USD","LU0058720904.USD","LU0109394709.USD","BK4532","BK4094","LU1585245621.USD","LU1066051498.USD","REGN","LU2362541513.USD","BK4566","LU1974910355.USD","LU1839511570.USD","IE00BKVL7J92.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2516654069","title":"AHCO vs. ABT: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516654069","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516654069?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:40","pubTimestamp":1741020026,"startTime":"0","endTime":"0","summary":"Investors interested in Medical - Products stocks are likely familiar with AdaptHealth Corp.  and Abbott . But which of these two stocks offers value investors a better bang for their buck right now?We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.AHCO currently has a forward P/E ratio of 10.25, while ABT has a forward P/E of 26.82. We also note that AHCO has a PEG ratio of 1.12. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ABT currently has a PEG ratio of 2.57.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ahco-vs-abt-stock-better-164026618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1691799644.USD","BK4175","LU2112291526.USD","BK4533","LU1989763427.SGD","LU1057294990.SGD","LU2237957902.USD","LU0170899867.USD","IE0002141913.USD","LU2237957811.SGD","SGXZ23171101.USD","LU1989763690.USD","IE00BJJMRZ35.SGD","BK4566","LU0266013472.USD","BK4581","ABT","LU1023059063.AUD","LU2089984988.USD","SG9999004303.SGD","LU1721429741.USD","IE00BJT1NW94.SGD","LU0234572021.USD","SG9999002232.USD","AHCO","LU0868494617.USD","LU0122379950.USD","SG9999002224.SGD","LU1914381329.SGD","BK4082","IE00B2B36J28.USD","BK4504","BK4568","IE00BFTCPJ56.SGD","BK4585","BK4588","LU1721429402.USD","LU2133065610.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","BK4592","LU1061106388.HKD"],"gpt_icon":0},{"id":"2516483653","title":"Pfizer could use existing US manufacturing to counter potential tariff hit","url":"https://stock-news.laohu8.com/highlight/detail?id=2516483653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516483653?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:23","pubTimestamp":1741018996,"startTime":"0","endTime":"0","summary":"UPDATE 2-Pfizer could use existing US manufacturing to counter potential tariff hitAdds background in paragraphs 5-8By Christy Santhosh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM17A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0321505439.SGD","LU0456855351.SGD","IE000M9KFDE8.USD","LU0170899867.USD","LU0321505868.SGD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0985481810.HKD","LU1057294990.SGD","IE00BLSP4239.USD","LU0306806265.USD","SGXZ57979304.SGD","BK4534","LU0058720904.USD","LU0868494617.USD","BK4533","LU1023059063.AUD","IE0002270589.USD","SG9999003800.SGD","SG9999001176.USD","LU0234572021.USD","SG9999001176.SGD","BK4588","LU1066051498.USD","LU1894683264.USD","SG9999011175.SGD","IE00BBT3K403.USD","BK4599","SG9999002224.SGD","PFE","SG9999013999.USD","SG9999002232.USD","LU0306807586.USD","LU1066053197.SGD","BK4585","BK4550","IE00B19Z3B42.SGD","LU1894683348.USD","BK4568","LU0225284248.USD","BK4007","LU1883839398.USD","BK4581","LU0122379950.USD","LU0225771236.USD","BK4592"],"gpt_icon":1},{"id":"2516653170","title":"Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653170","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653170?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:22","pubTimestamp":1741018934,"startTime":"0","endTime":"0","summary":"Ocugen  said Monday that the European Medicines Agency's Committee for Advanced Therapies issued a positive opinion granting Advanced Therapy Medicinal Product classification for its OCU410 and OCU410ST gene therapy candidates, which are being developed to treat vision loss caused by geographic atrophy and Stargardt disease.Dosing in the Phase 2 portion of the OCU410 clinical trial has been completed, and Ocugen expects to begin a Phase 3 trial next year, with plans to pursue regulatory approval in the US and Europe in 2028.Last week, the US Food and Drug Administration endorsed Ocugen's plan to initiate a Phase 2/3 pivotal confirmatory trial for OCU410ST, which could support future biologics license and marketing authorization applications in the US and EU, respectively.If approved, OCU410 could become the first treatment available in Europe for geographic atrophy, a late-stage form of dry age-related macular degeneration. While two therapies are currently approved in the US, neither ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B7SZL793.SGD","AEIS","BK6522","BK4563","IE0031619046.USD","IE00B66KJ199.SGD","BK4157","BLZ.SI","IE00B19Z4B17.USD","BK6088","BK4139","OCGN","BK4568"],"gpt_icon":0},{"id":"2516653634","title":"Gilead Sciences sets aside $200 million to resolve HIV drug probe","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653634","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653634?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:18","pubTimestamp":1741018712,"startTime":"0","endTime":"0","summary":"Gilead Sciences sets aside $200 million to resolve HIV drug probeBy Luc Cohen NEW YORK, March 3 (Reuters) - Gilead Sciences GILD.O set aside $200 million for a potential settlement with federal prosec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL2N3PM0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU1839511570.USD","LU2468319806.SGD","GILD","IE00BSNM7G36.USD","IE0002270589.USD","LU0234570918.USD","BK4550","LU1571399168.USD","BK4578","LU0109394709.USD","IE00B19Z3581.USD","LU0320765992.SGD","LU0889565916.HKD","LU1066051498.USD","LU1430594728.SGD","BK4532","BK4139","BK4585","LU2087621335.USD","LU0058720904.USD","BK4588","IE00B3T34201.USD","BK4568","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4583","LU1066053197.SGD","BK4566","IE00BKVL7J92.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2516656745","title":"KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656745","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656745?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:59","pubTimestamp":1741017540,"startTime":"0","endTime":"0","summary":"Krystal BiotechKRYS announced that the European Medicines Agency'sCommittee for Medicinal Products for Human Use  has adopted a positive opinion recommending the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa . The intended DEB patient population includes those who have mutations in the COL7A1 gene starting from birth.DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. Vyjuvekis a non-invasive, topical, redosable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds.In the past three months, shares of Krystal Biotech have plunged 18.3% compared with the industry’s 0.6% decline.More on CHMP’s Positive Opinion on Vyjuvek’s EU Approval. The positive CHMP opinion recommending the approval of Vyjuvekfor the DEB indication in the EU is based on the results of Krystal Biotech’s phase I/II GEM-1 and phase","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krys-gets-positive-chmp-opinion-155900015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171311.SGD","IE00B19Z3581.USD","KRYS","LU0234570918.USD","LU1585245621.USD","GILD","LU1839511570.USD","IE00B3T34201.USD","LU2065169927.USD","LU2087621335.USD","LU0289739699.SGD","LU2065171402.SGD","CHMP","BK4156","LU1430594728.SGD","LU2089984988.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","IE0002270589.USD","LU2065170008.USD","BK4139","BK4588","LU2468319806.SGD","BK4583","IE00B7SZLL34.SGD","LU0320765992.SGD","LU1066051498.USD","IE00BSNM7G36.USD","BK4087","LU1066053197.SGD","BK4585","BK4550","BK4532","BMRN","IE00B19Z3B42.SGD","LU1571399168.USD","FOLD","BK4568","IE00BKVL7J92.USD","LU0889565916.HKD","BK4566","BK4578","LU0109394709.USD"],"gpt_icon":0},{"id":"2516186658","title":"Pfizer could move outside manufacturing to the US, says CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516186658","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516186658?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:56","pubTimestamp":1741017393,"startTime":"0","endTime":"0","summary":"Pfizer could move outside manufacturing to the US, says CEOMarch 3  - Pfizer PFE.N CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to the U.S., if required, as President Donald Trump's administration threatens numerous tariffs on imported goods.   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM16E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","LU0306807586.USD","SG9999003800.SGD","LU0122379950.USD","LU0868494617.USD","LU1057294990.SGD","LU1066053197.SGD","SG9999002232.USD","LU0306806265.USD","LU1894683264.USD","SG9999011175.SGD","BK4550","BK4581","LU0321505439.SGD","LU0289739699.SGD","LU1894683348.USD","SG9999013999.USD","IE00BLSP4452.SGD","BK4588","BK4007","BK4533","IE00BBT3K403.USD","LU0321505868.SGD","LU1883839398.USD","LU1023059063.AUD","SG9999001176.SGD","LU1066051498.USD","BK4568","PFE","BK4592","SG9999001176.USD","BK4599","LU0058720904.USD","SG9999002224.SGD","IE00B19Z3581.USD","LU0170899867.USD","BK4534","BK4585","LU0225771236.USD","IE0002270589.USD","LU0234572021.USD","LU0456855351.SGD","LU0985481810.HKD","IE000M9KFDE8.USD","LU0225284248.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2516653392","title":"Pfizer comments on Q1, Q2 numbers amid higher rebate expense","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653392","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653392?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:55","pubTimestamp":1741017358,"startTime":"0","endTime":"0","summary":"Says “I don’t think the Street” has adjusted yet and that “they should have a look on it.” The company says the rebates that Pfizer (PFE) will be a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pfizer-comments-on-q1-q2-numbers-amid-higher-rebate-expense?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pfizer-comments-on-q1-q2-numbers-amid-higher-rebate-expense?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","IE0002270589.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4534","LU0122379950.USD","LU1894683264.USD","BK4592","IE00BLSP4239.USD","BK4588","LU1894683348.USD","LU0289739699.SGD","LU0868494617.USD","LU1066053197.SGD","SG9999013999.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4007","IE00B19Z3581.USD","LU0306806265.USD","LU1066051498.USD","LU0321505868.SGD","BK4585","LU1883839398.USD","LU0170899867.USD","LU0306807586.USD","LU0225284248.USD","SG9999002232.USD","BK4581","IE00B19Z3B42.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4568","LU0058720904.USD","SGXZ57979304.SGD","SG9999001176.USD","LU0225771236.USD","LU0456855351.SGD","PFE","BK4533","BK4599","LU0985481810.HKD","LU0234572021.USD"],"gpt_icon":0},{"id":"2516563076","title":"Pfizer Exec Says IF There Are Significant Tariffs, Co Will TRY to Move Outside Manufacturing to the U.S.- TD Cowen Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516563076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516563076?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:38","pubTimestamp":1741016294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PFE","SG9999013999.USD","LU0225284248.USD","SGXZ57979304.SGD","BK4007","LU0058720904.USD","IE00BBT3K403.USD","IE00BLSP4239.USD","BK4533","IE00B19Z3B42.SGD","LU0122379950.USD","SG9999003800.SGD","LU0225771236.USD","LU0306806265.USD","LU0985481810.HKD","LU0456855351.SGD","BK4588","BK4592","LU0234572021.USD","BK4568","LU0306807586.USD","LU0321505439.SGD","LU1023059063.AUD","IE00B19Z3581.USD","BK4550","LU0289739699.SGD","LU1057294990.SGD","LU1894683348.USD","SG9999011175.SGD","IE000M9KFDE8.USD","LU0170899867.USD","LU1883839398.USD","BK4581","SG9999002232.USD","BK4534","SG9999001176.SGD","LU0321505868.SGD","LU1894683264.USD","IE0002270589.USD","BK4585","LU1066051498.USD","LU1066053197.SGD","LU0868494617.USD","SG9999002224.SGD","SG9999001176.USD","BK4599","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2516637517","title":"Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516637517?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:07","pubTimestamp":1741014467,"startTime":"0","endTime":"0","summary":"Roivant Sciences'  subsidiary Genevant Sciences and Arbutus Biopharma  said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.Moderna did not i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4533","BK4501","BK4532","BK4588","BK4534","ABUS","BK4568","BK4551","ROIV","BK4548","BK4139","BK4007"],"gpt_icon":1},{"id":"2516329226","title":"BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification","url":"https://stock-news.laohu8.com/highlight/detail?id=2516329226","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516329226?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:53","pubTimestamp":1741013593,"startTime":"0","endTime":"0","summary":"BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification March 3 (Reuters) - Ocugen Inc OCGN.O:OCUGEN ANNOUNCES POSITIVE OPINION OF EMA’S COMMITTEE FOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM10Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","OCGN","BK4568"],"gpt_icon":0},{"id":"2516653171","title":"Novartis Gets CHMP Opinion for Label Expansion of Fabhalta","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653171","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653171?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:39","pubTimestamp":1741012740,"startTime":"0","endTime":"0","summary":"Novartis NVS announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ((iptacopan).Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway 6-7.The CHMP recommended granting a marketing authorization to Fabhalta for the treatment of adults with C3 glomerulopathy , an ultra-rare, progressive kidney disease with no currently approved treatments.A final decision from the European Commission  is expected in two months.The CHMP’s positive opinion is based on robust data from APPEAR-C3G, a randomized placebo-controlled phase III study. The study showed patients treated with Fabhalta, in addition to supportive care, achieved a statistically significant and clinically meaningful 35.1% reduction in proteinuria  at 6 months when compared to placebo.A potential approval will make Fabhalta the only drug indicated to target the underlying cause of C3G.Shares of Novartis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-gets-chmp-opinion-label-143900090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","GILD","BK4585","IE00B4R5TH58.HKD","IE00BKVL7J92.USD","LU2468319806.SGD","IE0002141913.USD","LU1839511570.USD","LU2087621335.USD","IE00BJJMRZ35.SGD","LU1066053197.SGD","BK4532","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2089984988.USD","CHMP","IE00B7SZLL34.SGD","BK4550","LU0234570918.USD","IE0009355771.USD","BK4201","IE00BSNM7G36.USD","BK4007","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1571399168.USD","IE00BJT1NW94.SGD","IE0002270589.USD","BK4568","BMRN","BK4583","LU0889565916.HKD","LU0211331839.USD","NVS","IE00B3T34201.USD","BK4578","LU0320765992.SGD","BK4087","IE00B19Z3B42.SGD","EC","BK4139","IE00B2B36J28.USD","LU1585245621.USD","BK4566","BK4588","LU1430594728.SGD","LU0289739699.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2516634639","title":"Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634639","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634639?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:30","pubTimestamp":1741012200,"startTime":"0","endTime":"0","summary":"The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India. SALT LAKE CITY, March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara Diagnostics Pvt. Ltd. , the joint venture between Ambalal Sarabhai Enterprises Limited  and Co-Dx, will be hosting a symposium to honor International HPV  Awareness Day 2025.CoSara CEO Mohal Sarabhai added \"In alignment with the missions of the joint venture partners, CoSara is committed to a world with increased access to high-quality infectious disease diagnostics. We believe that providing a forum for leading experts in fields like HPV and cancer to share knowledge with other researchers, physicians, oncologists and industr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/co-diagnostics-inc-cosara-host-143000118.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/co-diagnostics-inc-cosara-host-143000118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4588","BK4568","CODX","BK4585","BK4218","BK4082","HST"],"gpt_icon":0},{"id":"2516313176","title":"Genevant: Seeking Monetary Relief, Injunctions Against Spikevax &, Where Applicable, Additional Products That Moderna Represented Use Same Lnp Tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2516313176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516313176?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:15","pubTimestamp":1741011309,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA4YDVCV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4501","ABUS","BK4588","ROIV","BK4533","BK4568","BK4007","BK4551","BK4534","BK4532","BK4548","BK4585","BK4139","MRNA"],"gpt_icon":0}],"pageSize":16,"totalPage":19,"pageCount":17,"totalSize":290}]}}